Alex Denner’s Sarissa Capital Management Lp Disclosed New Regulus Therapeutics Inc Position

Regulus Therapeutics Inc. (NASDAQ:RGLS) Logo

The New Alex Denner’s Sarissa Capital Management Lp Holding in Regulus Therapeutics Inc

Sarissa Capital Management Lp reported SC 13D form with the SEC for Regulus Therapeutics Inc. Access it here: 000089914019000406. As reported by Alex Denner’s Sarissa Capital Management Lp, the filler owns 16.53% or 3,703,702 shares of the Health Care–company.

Regulus Therapeutics Inc stake is new for [reportingPerson]. Date of activity: May 7, 2019. This shows Alex Denner’s Sarissa Capital Management Lp’s positive view for Regulus Therapeutics Inc. For a hedge fund managing $595.73 million in assets and having 8+ experts this is interesting position.

The hedge fund is investor in the Health Care sector. In the manager’s last 13-F, we saw 12% of Alex Denner’s Sarissa Capital Management Lp’s portfolio is in the sector.

Reasons Why Alex Denner’s Sarissa Capital Management Lp Bought – Regulus Therapeutics Inc Stock

Item 4. Purpose of Transaction

On May 3, 2019, Sarissa Offshore, Sarissa Catapult and Sarissa Hawkeye entered into a securities purchase agreement with the Issuer and the other investors identified therein (the “Purchase Agreement”), pursuant to which the Issuer agreed to issue and sell (i) Shares, (ii) shares of newly designated non-voting convertible preferred stock

of the Issuer (the “Preferred Stock”) and (iii) accompanying warrants to purchase Shares

, in up to two closings, in a private placement transaction.

Pursuant to the Purchase Agreement, at the initial closing which occurred on May 7, 2019 (the “Initial Closing”),

(i) for a purchase price of $1.08 per Share, (a) Sarissa Offshore purchased from Issuer 1,172,892 Shares, (b) Sarissa Catapult purchased from Issuer 382,356 Shares and (c) Sarissa Hawkeye purchased from Issuer 296,603 Shares and (ii) for a purchase price of $0.125 per Share underlying the applicable Warrant, (a) Sarissa Offshore purchased from Issuer Warrants to purchase 1,172,892 Shares (b) Sarissa Catapult purchased from Issuer Warrants to purchase 382,356 Shares, and (c) Sarissa Hawkeye purchased from Issuer Warrants to purchase 296,603 Shares.

The Warrants will be exercisable for a period of five years following the date of issuance and will have an exercise price of $1.08 per share, subject to proportional adjustments in the event of stock splits or combinations or similar events. The Warrants are exercisable on a net exercise “cashless” basis.

Pursuant to the Purchase Agreement, in the event that the Issuer’s Board of Directors unanimously resolves to recommence the Issuer’s Phase 1 clinical trial of the Issuer’s RGLS4326 product candidate (the “Phase 1 Trial”) based on correspondence from the U.S. Food & Drug Administration’s Division of Cardiovascular and Renal Products, and thereafter but on or before December 31, 2019 the Issuer makes a public announcement of its plan to recommence the Phase 1 Trial, the Issuer has agreed to sell and the Reporting Persons have agreed to purchase, at a second closing under the Purchase Agreement (the “Milestone Closing”), shares of Preferred Stock and accompanying Warrants to purchase Shares for an aggregate purchase price of approximately $3 million for the shares of Preferred Stock and $347,000 for the Warrants, excluding the exercise price of such Warrants, or $10.80 per share of Preferred Stock and $0.125 per Share

underlying the Warrant

. Each share of Preferred Stock is convertible into 10 Shares, subject to certain beneficial ownership conversion limitations set forth in the Purchase Agreement.

Under the terms of the Purchase Agreement, the Issuer has agreed to prepare and file, within 30 days after the Initial Closing and within 30 days after the Milestone Closing, if necessary, one or more registration statements with the

U.S. Securities and Exchange Commission

to register for resale the Shares issued under the Purchase Agreement, the Shares issuable upon exercise of the Warrants, and the Shares issuable upon conversion of any Preferred Stock issued pursuant to the Purchase Agreement, and generally to cause the applicable registration statements to become effective within 90 days after the applicable closing under the Purchase Agreement. Certain cash penalties will apply to the Issuer in the event of registration failures, as described in the Purchase Agreement.

CUSIP No. 75915K200

Page 9 of 13 Pages

SCHEDULE 13D

The Reporting Persons may, from time to time and at any time, (i)acquire additional Shares and/or other equity, debt, notes, instruments or other securities (collectively, “Securities”) of the Issuer in the open market or otherwise; (ii)dispose of any or all of their Securities in the open market or otherwise; or (iii)engage in any hedging or similar transactions with respect to the Securities.

The Purchase Agreement is attached as Exhibit 10.1 to the Form 8-K of the Issuer filed with the U.S. Securities and Exchange Commission on May 9, 2019 and is incorporated by reference in this Schedule 13D;

any description herein of the Purchase Agreement is qualified in its entirety by reference to the Purchase Agreement so filed by the Issuer. The form of Warrant is

attached as Exhibit 4.2 to the Form 8-K of the Issuer filed with the U.S. Securities and Exchange Commission on May 9, 2019 and is incorporated by reference in this Schedule 13D;

any description herein of the Form of Warrant is qualified in its entirety by reference to the Form of Warrant so filed by the Issuer

.

The Certificate of Designations for the Preferred Stock is

attached as Exhibit 3.1 to the Form 8-K of the Issuer filed with the U.S. Securities and Exchange Commission on May 9, 2019 and is incorporated by reference in this Schedule 13D;

any description herein of the Preferred Stock is qualified in its entirety by reference to the Certificate of Designations for the Preferred Stock so filed by the Issuer

.

Regulus Therapeutics Inc Institutional Sentiment

Filings show 41 investors own Regulus Therapeutics Inc. The ownership in Q3 2017 is low, at Infinity of the outstanding shares. This is increased by 36427625. 58846745 were owned by these investors. 11 funds opened new Regulus Therapeutics Inc stakes, 16 increased positions. There were 9 that closed positions and 11 reduced them.

Nea Management Company Llc is an investor bullish on Regulus Therapeutics Inc, owning 10989910 shares as of Q3 2017 for 0.48% of its portfolio. Ecor1 Capital Llc owns 5239225 shares or 0.87% of its portfolio. CA Dowling & Yahnke Llc have less than 0.01% of its portfolio for 11500 shares. Further, Bvf Inc reported stake worth 2.06% of its portfolio. The CT Bourgeon Capital Management Llc owns 40804 shares. Regulus Therapeutics Inc is 0.03% of its portfolio.

SEC Form 13D.

Alex Denner’s Sarissa Capital Management Lp website.

The stock decreased 2.52% or $0.03 during the last trading session, reaching $1.16. About 477,811 shares traded or 109.10% up from the average. Regulus Therapeutics Inc. (NASDAQ:RGLS) has declined 91.05% since May 17, 2018 and is downtrending. It has underperformed by 95.42% the S&P500.

Regulus Therapeutics Inc., a biopharmaceutical company, focuses on the discovery and development of drugs that target microRNAs to treat a range of diseases in the United States. The company has market cap of $12.55 million. The firm uses its microRNA product platform to develop anti-miRs, which are chemically modified and single-stranded oligonucleotides. It currently has negative earnings. The Company’s clinical development products include RG-101, a GalNAc-conjugated anti-miR targeting miR-122 to treat patients with hepatitis C virus infection; RG-012, an anti-miR targeting microRNA-21 for the treatment of Alport syndrome; RG-125, a GalNAc-conjugated anti-miR targeting microRNA-103/107 for the treatment of non-alcoholic fatty liver disease; RGLS5040, an anti-miR targeting microRNA-27 for the treatment of cholestatic disease; and RGLS4326, an anti-miR targeting microRNA-17 for the treatment of autosomal dominant polycystic kidney disease.

Regulus Therapeutics Inc. (NASDAQ:RGLS) Ratings Coverage

Among 2 analysts covering Regulus Therapeutics (NASDAQ:RGLS), 0 have Buy rating, 0 Sell and 2 Hold. Therefore 0 are positive. Regulus Therapeutics has $2 highest and $1.5 lowest target. $1.75’s average target is 50.86% above currents $1.16 stock price. Regulus Therapeutics had 7 analyst reports since February 26, 2019 according to SRatingsIntel. The company was maintained on Tuesday, March 19 by Wells Fargo. Wedbush maintained it with “Hold” rating and $2 target in Tuesday, March 26 report.

More notable recent Regulus Therapeutics Inc. (NASDAQ:RGLS) news were published by: Seekingalpha.com which released: “SBGI, AMG, GIII and ZNH among notable midday movers – Seeking Alpha” on May 06, 2019, also Seekingalpha.com with their article: “Regulus -48.4% as it slashes 60% of workforce to stretch cash – Seeking Alpha” published on July 05, 2018, Seekingalpha.com published: “Regulus up 12% on improved finances – Regulus Therapeutics Inc. (NASDAQ:RGLS) – Seeking Alpha” on May 06, 2019. More interesting news about Regulus Therapeutics Inc. (NASDAQ:RGLS) were released by: Seekingalpha.com and their article: “Regulus: A ‘Lottery Ticket’ Only For The Brave-Hearted – Seeking Alpha” published on August 23, 2017 as well as Seekingalpha.com‘s news article titled: “RG-101 Clinical Hold Offers Investment Opportunity For Regulus Therapeutics – Seeking Alpha” with publication date: November 14, 2016.

Regulus Therapeutics Inc. (NASDAQ:RGLS) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.